Wash U Team Finds Genomic Profile May Predict Aromatase Inhibitor Response in Breast Cancer Patients | GenomeWeb

NEW YORK (GenomeWeb News) – Using whole-genome sequencing in a clinical trial of aromatase-inhibitor therapy for estrogen-positive breast cancer patients, researchers from the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and the Genome Institute at Washington University in St. Louis have found genomic signatures that correlate with drug response and resistance.

The study's results were published online Sunday in Nature.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.